Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for propranolol
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on propranolol or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on propranolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
WITHDRAWN: Propranolol for migraine prophylaxis. Propranolol is one of the most commonly prescribed drugs for migraine prophylaxis.We aimed to determine whether there is evidence that propranolol is more effective than placebo and as effective as other drugs for the interval (prophylactic) treatment of patients with migraine.Potentially eligible studies were identified by searching MEDLINE/PubMed (1966 to May 2003) and the Cochrane Central Register of Controlled Trials (Issue 2, 2003 (...) ), and by screening bibliographies of reviews and identified articles.We included randomised and quasi-randomised clinical trials of at least 4 weeks duration comparing clinical effects of propranolol with placebo or another drug in adult migraine sufferers.Two reviewers extracted information on patients, methods, interventions, outcomes measured, and results using a pre-tested form. Study quality was assessed using two checklists (Jadad scale and Delphi list). Due to the heterogeneity of outcome measures
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. The objective of this article is to see whether the effect of candesartan for migraine prevention, shown in one previous study, could be confirmed in a new study, and if so, whether the effect was comparable to that of propranolol (non-inferiority analysis), and whether adverse events were different.In a randomised, triple-blind, double cross (...) -over study, 72 adult patients with episodic or chronic migraine went through three 12-week treatment periods on either candesartan 16 mg, propranolol slow-release 160 mg, or placebo. The main outcome measures were days with migraine headache per four weeks (primary outcome), days with headache, hours with headache, proportion of responders (>50% reduction of migraine days from baseline), and adverse events.In the modified intention-to treat-analysis, candesartan and propranolol were both superior
Propranolol USE OF PROPRANOLOL IN PREGNANCY 0344 892 0909 USE OF PROPRANOLOL IN PREGNANCY (Date of issue: March 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Propranolol is a non-selective beta-adrenoceptor blocking drug (...) propranolol exposure and women should be made aware of this lack of data. Studies of beta-blockers as a class have not, to date, provided conclusive evidence that use during pregnancy is associated with an increased risk of fetal structural malformations. Although some studies have suggested a possible increased risk of congenital heart defects, this has also been observed with other antihypertensive therapies and may therefore be non-drug-specific or linked to the underlying maternal condition. A meta
Propranolol vs Prednisolone for Symptomatic Proliferating Infantile Hemangiomas: A Randomized Clinical Trial. While propranolol is touted as superior to prednisolone for treating infantile hemangiomas (IH), a randomized clinical trial (RCT) comparing the outcome and tolerability of these medications for symptomatic, proliferating IH has not been reported.To determine if oral propranolol is more efficacious and better tolerated than prednisolone in treating symptomatic, proliferating IH (...) and to determine the feasibility of conducting a multi-institutional, RCT comparing efficacy and tolerability of both medications.Phase 2, investigator-blinded, multi-institutional RCT conducted in 3 academic vascular anomalies clinics on 19 of 44 eligible infants aged between 2 weeks and 6 months. All participating patients had symptomatic proliferating IH treated between September 1, 2010, and August 1, 2012.Treatment with oral propranolol vs prednisolone (2.0 mg/kg/d) until halted owing to toxic effects
The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02385422 Recruitment Status : Unknown Verified March 2015 by Shiyao Chen, Shanghai Zhongshan Hospital. Recruitment status was: Recruiting First Posted
Comparison of propranolol and pregabalin for prophylaxis of childhood migraine: a randomised controlled trial. Migraine involves 5-10% of children and adolescents. Thirty percent of children with severe migraine attacks have school absence and reduced quality of life that need preventive therapy. The purpose of this randomised control trial study is to compare the effectiveness, safety and the tolerability of pregabalin toward Propranolol in migraine prophylaxis of children. From May 2011 (...) to October 2012, 99 children 3-15 years referred to the neurology clinic of Mofid Children's Hospital with a diagnosis of migraine enrolled the study. Patients randomly divided into two groups (A&B). We treated children of group A with capsule of pregabalin as children of group B with tablet of propranolol for at least 8 weeks. In this study, 99 patients were examined that 91 children reached the last stage. The group A consistsed of 46 patients, 12(26.1%) girls, 34 (73.9%) boys and the group B consisted
Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review Given the widespread use of propranolol in infantile hemangioma (IH) it was considered essential to perform a systematic review of its safety. The objectives of this review were to evaluate the safety profile of oral propranolol in the treatment of IH.We searched Embase and Medline databases (2007-July 2014) and unpublished data from the manufacturer of Hemangiol/Hemangeol (marketed pediatric formulation (...) of oral propranolol; Pierre Fabre Dermatologie, Lavaur, France). Selected studies included ≥10 patients treated with oral propranolol for IH and that either reported ≥1 adverse event or effect (AE) or planned to capture AEs. Data capture was standardized and extracted study design, demographic characteristics, IH characteristics, intervention, and safety outcomes. AEs were assigned a system organ class and preferred term.A total of 83 of 398 identified literature records met the inclusion criteria
Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery. Animal and human research suggests that the development of posttraumatic stress disorder (PTSD) may involve the overconsolidation of memories of a traumatic experience. Previous studies have attempted to use pharmaceutical agents, especially the β-adrenergic blocker propranolol, to reduce this overconsolidation.In this randomized, placebo-controlled study of the efficacy (...) of propranolol in reducing the development of PTSD, we optimized dosages and conducted both psychophysiological and clinical assessments 1 and 3 months after the traumatic event. Forty-one emergency department patients who had experienced a qualifying acute psychological trauma were randomized to receive up to 240 mg/day of propranolol or placebo for 19 days. At 4 and 12 weeks post-trauma, PTSD symptoms were assessed. One week later, participants engaged in script-driven imagery of their traumatic event
Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. To assess the efficacy and safety of adding propranolol to topiramate in chronic migraine subjects inadequately controlled with topiramate alone.This was a double-blind, placebo-controlled, randomized clinical trial conducted through the National Institute of Neurological Disorders and Stroke Clinical Research Collaboration, expected to randomize 250 chronic migraine subjects inadequately controlled (...) (≥10 headaches/month) with topiramate (50-100 mg/day) to either propranolol LA (long acting) (240 mg/day) or placebo. Primary outcome was 28-day moderate to severe headache rate reduction at 6 months (weeks 16 to 24) compared with baseline (weeks -4 to 0).A planned interim analysis was performed after 48 sites randomized 171 subjects. The data and safety monitoring board recommended ending the trial after determining that it would be highly unlikely for the combination to result in a significant
Prophylactic propranolol for prevention of ROP and visual outcome at 1 year (PreROP trial). To evaluate the role of prophylactic propranolol in the prevention of retinopathy of prematurity (ROP) in infants ≤32 weeks of gestational age and their visual outcome at 1 year of corrected gestational age.Randomised double blind placebo controlled trial, parallel group nrolment with allocation ratio of 1:1.Two level III neonatal intensive care units.109 preterm neonates of ≤32 weeks of gestation (...) with postnatal age ≤8 days old.Study group: Infants with gestational age between 26 and 32 weeks were started on propranolol prophylaxis (0.5 mg/kg/dose every 12 hours) on seventh completed day of life, till a corrected gestational age of 37 weeks or complete vascularisation of retina whichever was later. Control group infants received a placebo.Primary: ROP of all grades; Secondary: evaluation of complications due to propranolol, ROP needing treatment with laser and/or antivascular endothelial growth factor
Nonpharmacologic treatment of migraine with low-dose propranolol or amitriptyline. This study evaluated the effectiveness of nonpharmacologic measures combined with low-dose propranolol or amitriptyline for treating severe pediatric migraine. Data were collected from the medical files of 118 patients (mean age, 12.54 ± 3.14 years S.D.). All were treated with nonpharmacologic measures. In addition, 93 children received propranolol (mean initial dose, 0.4 ± 0.17 mg/kg/day S.D.), and 25 received (...) amitriptyline (mean initial dose, 0.26 ± 0.1 mg/kg/day S.D.). Twenty patients were switched from propranolol to amitriptyline during treatment. In both groups, headache frequency was reduced by >50% per month in ~80% of patients. Patients without aura responded significantly better to propranolol than patients with aura (P = 0.02). No significant difference was evident in response to pharmacologic treatment by migraine frequency or type (episodic chronic). No significant difference was evident in response
Propranolol treatment of thyrotoxicosis in a premature infant. 912277 1977 12 29 2018 11 13 0007-1447 2 6089 1977 Sep 17 British medical journal Br Med J Propranolol treatment of thyrotoxicosis in a premature infant. 738 Pearl K N KN Chambers T L TL eng Case Reports Journal Article England Br Med J 0372673 0007-1447 9Y8NXQ24VQ Propranolol AIM IM Humans Hyperthyroidism drug therapy Infant, Newborn Infant, Premature, Diseases drug therapy Male Propranolol therapeutic use 1977 9 17 1977 9 17 0 1
Preliminary report on the use of propranolol in thyrotoxicosis: I. Effect on serum thyroxine, triiodothyronine and reverse triiodothyronine concentrations. 688126 1978 11 22 2018 11 13 0008-4409 119 4 1978 Aug 26 Canadian Medical Association journal Can Med Assoc J Preliminary report on the use of propranolol in thyrotoxicosis: I. Effect on serum thyroxine, triiodothyronine and reverse triiodothyronine concentrations. 350-1, 360 Tevaarwerk G J GJ Malik M H MH Boyd D D eng Journal Article Canada (...) Can Med Assoc J 0414110 0008-4409 06LU7C9H1V Triiodothyronine 5817-39-0 Triiodothyronine, Reverse 9Y8NXQ24VQ Propranolol Q51BO43MG4 Thyroxine AIM IM Adult Aged Female Humans Hyperthyroidism blood drug therapy Male Middle Aged Propranolol therapeutic use Thyroxine blood Triiodothyronine blood Triiodothyronine, Reverse blood 1978 8 26 1978 8 26 0 1 1978 8 26 0 0 ppublish 688126 PMC1818352 Acta Endocrinol (Copenh). 1963 May;43:131-6 13928828 N Engl J Med. 1957 Sep 5;257(10):435-42 13464954 J Clin
Remission of Thyrotoxicosis during Treatment with Propranolol Twenty-eight thyrotoxic patients were treated with propranolol. In seven patients the drug had to be discontinued after one or two months, but in the remaining 21 clinical improvement was observed. Serial clinical studies and tests of thyroid function performed at monthly intervals showed that in four patients thyrotoxicosis remitted and all indices of thyroid function returned to normal. A fifth patient shows distinct evidence (...) of remission with the 20-minute (132)I uptake falling to normal, although the free-thyroxine index remains slightly raised. It is likely that these remissions reflect the natural tendency of the disease to remit since propranolol is not considered to have any direct in-vivo effect on thyroid function.However, because of failure to gain adequate control of symptoms in all patients treated, and the fact that circulating thyroid hormone levels were often not restored to normal, propranolol is considered
Decreasing adrenergic or sympathetic hyperactivity after severe traumatic brain injury using propranolol and clonidine (DASH After TBI Study): study protocol for a randomized controlled trial. Severe TBI, defined as a Glasgow Coma Scale ≤ 8, increases intracranial pressure and activates the sympathetic nervous system. Sympathetic hyperactivity after TBI manifests as catecholamine excess, hypertension, abnormal heart rate variability, and agitation, and is associated with poor neuropsychological (...) outcome. Propranolol and clonidine are centrally acting drugs that may decrease sympathetic outflow, brain edema, and agitation. However, there is no prospective randomized evidence available demonstrating the feasibility, outcome benefits, and safety for adrenergic blockade after TBI.The DASH after TBI study is an actively accruing, single-center, randomized, double-blinded, placebo-controlled, two-arm trial, where one group receives centrally acting sympatholytic drugs, propranolol (1 mg
Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Endoscopic Band Ligation (EBL) Versus Propranolol for Primary Prophylaxis of Variceal Bleeding The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT00965900 Recruitment Status : Recruiting
Candesartan Versus Propranolol for Migraine Prevention Candesartan Versus Propranolol for Migraine Prevention - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Candesartan Versus Propranolol for Migraine (...) Information provided by (Responsible Party): Norwegian University of Science and Technology Study Details Study Description Go to Brief Summary: The main aim of the present study is to compare candesartan with propranolol for migraine prophylaxis. Condition or disease Intervention/treatment Phase Migraine Without Aura Migraine With Aura Chronic Migraine Drug: Candesartan Drug: propranolol Drug: placebo Phase 2 Phase 3 Detailed Description: Candesartan was shown to be effective for migraine prophylaxis
Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial. The authors assessed the efficacy of trauma memory reactivation performed under the influence of propranolol, a noradrenergic beta-receptor blocker, as a putative reconsolidation blocker, in reducing symptoms of posttraumatic stress disorder (PTSD).This was a 6-week, double-blind, placebo-controlled, randomized clinical trial in 60 adults diagnosed with long-standing PTSD. Propranolol or placebo (...) was administered 90 minutes before a brief memory reactivation session, once a week for 6 consecutive weeks. The hypothesis predicted a significant treatment effect of trauma reactivation with propranolol compared with trauma reactivation with placebo in reducing PTSD symptoms on both the Clinician-Administered PTSD Scale (CAPS) and the patient-rated PTSD Checklist-Specific (PCL-S) in an intention-to-treat analysis.The estimated group difference in posttreatment CAPS score, adjusted for pretreatment values
Propranolol generally safe in treating childhood haemangioma birthmarks Propranolol generally safe in treating childhood haemangioma birthmarks Discover Portal Discover Portal Propranolol generally safe in treating childhood haemangioma birthmarks Published on 17 January 2017 doi: Treating ‘infantile haemangioma’ strawberry birthmarks with oral propranolol is known to be effective and in this review was associated with low levels of adverse events. The most common adverse events included (...) coldness in the hands and feet, diarrhoea, sleep disorders and upper respiratory infections. More serious problems such as low blood pressure, slow heart rate, over-reactivity of the airways and low blood sugar were also reported. Though rare, parents and prescribers need to be aware of these side effects. There is currently no UK guidance on treating haemangioma. The beta-blocker propranolol is usually used to treat heart conditions. Although commonly used, UK preparations of this drug
Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial Limited data are available on the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis (PVT). This study aimed to compare transjugular intrahepatic portosystemic shunt (TIPS) with covered stents versus endoscopic band ligation (EBL) plus propranolol for the prevention of variceal (...) rebleeding among patients with cirrhosis and PVT.Consecutive cirrhotic patients (94% Child-Pugh class A or B) with PVT who had variceal bleeding in the past 6 weeks were randomly assigned to TIPS group (n=24) or EBL plus propranolol group (EBL+drug, n=25), respectively. Primary endpoint was variceal rebleeding. Secondary endpoints included survival, overt hepatic encephalopathy (OHE), portal vein recanalisation and rethrombosis, other complications of portal hypertension and adverse events.During